Skip to main content
Pixium Vision logo

Pixium Vision — Investor Relations & Filings

Ticker · ALPIX ISIN · FR001400JX97 LEI · 96950046OPLRLKKEOO08 PA Manufacturing
Open in API
Filings indexed 440 across all filing types
Latest filing 2017-10-26 Earnings Release
Country FR France
Listing PA ALPIX

About Pixium Vision

https://www.pixium-vision.com/

Pixium Vision was a bioelectronics company that developed bionic vision systems to restore partial sight for patients with retinal diseases. Its core technology, the PRIMA System, is a photovoltaic subretinal implant designed to treat vision loss from advanced atrophic dry age-related macular degeneration (dry AMD). The system uses specialized glasses to project near-infrared light onto the implant, which converts the light into electrical signals to stimulate retinal cells and create a form of prosthetic vision. The company's assets, including the PRIMA technology and its ongoing European pivotal trial (PRIMAvera), were acquired by Science Corporation in late 2023. The trials and device manufacturing are now sponsored by La Science SAS.

Recent filings

Filing Released Lang Actions
Quarterly financial report / Third quarter financial report
Earnings Release Classification · 95% confidence The document is a press release from Pixium Vision detailing its third-quarter financial results (revenues and cash position) and providing an operational business update. While it contains financial data, it is a periodic update rather than a full interim report (IR). According to the classification rules, this type of announcement, which provides key highlights of financial performance and business developments, is best categorized as an Earnings Release (ER). 9M 2017
2017-10-26 English
Information financière trimestrielle / Information financière du troisième trimestre
Interim / Quarterly Report Classification · 95% confidence The document is a press release from Pixium Vision announcing its cash position as of September 30, 2017, and providing an update on its business activities, including clinical trials and financing. It contains substantive financial data (cash flow tables, operational products) for a period shorter than a full fiscal year. While it is an announcement, it provides detailed financial analysis and performance metrics for the nine-month period, fitting the definition of an Interim/Quarterly Report (IR) rather than a simple report publication announcement. 9M 2017
2017-10-26 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Capital/Financing Update Classification · 99% confidence The document is a press release dated October 23, 2017, announcing that Pixium Vision has established an 'equity line financing facility' with Kepler Cheuvreux. This facility involves the commitment to subscribe for shares over time, which directly relates to the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it is a specific announcement about securing financing, CAP is the most appropriate classification over the general 'Regulatory Filing' (RNS). The document length (7661 chars) is substantial enough to be the primary announcement itself, not just a notice of publication (RPA).
2017-10-23 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Capital/Financing Update Classification · 99% confidence The document is a press release dated October 23, 2017, announcing that Pixium Vision has established an Equity Line Financing agreement with Kepler Cheuvreux. This action involves securing future capital through the potential issuance of new shares, which directly relates to the company's financing activities and capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it is a specific announcement about a financing mechanism, CAP is the most appropriate classification over the general 'RPA' or 'RNS'.
2017-10-23 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated October 19, 2017, announcing that Pixium Vision has received authorization from the ANSM (French National Agency for the Safety of Medicines and Health Products) to start a clinical evaluation for its PRIMA subretinal implant for treating dry Age-related Macular Degeneration (AMD). This is a specific announcement regarding regulatory approval for a clinical trial, which is a form of corporate news release. It is not a full financial report (10-K, IR), a management discussion (MDA), an earnings release (ER), or a proxy statement (DEF 14A). Since it is a specific announcement of a significant corporate event (regulatory clearance for a clinical trial), it best fits the general 'Regulatory Filings' (RNS) category as a broad regulatory/corporate update, or potentially a specialized 'Legal Proceedings Report' (LTR) if viewed as regulatory interaction, but RNS is the most appropriate general regulatory announcement fallback when a more specific category like 'CAP' (financing) or 'TAR' (M&A) does not apply. Given the context of regulatory clearance for a medical device trial, RNS is the best fit among the provided options for a non-financial, non-governance, non-management specific announcement.
2017-10-19 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is a press release dated October 19, 2017, announcing that Pixium Vision received authorization from the French regulatory agency (ANSM) to start a feasibility clinical study for its PRIMA implant system for dry-AMD. This is a specific operational update concerning regulatory approval for a clinical trial, not a standard financial report (like 10-K, IR, ER) or a general shareholder communication (like AGM, DEF 14A). Since there is no specific category for 'Clinical Trial Approval' or 'Regulatory Approval for Medical Device,' the most appropriate general category for a significant, non-financial regulatory announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS). It is not a Call Transcript (CT), Earnings Release (ER), or a formal financial report (IR/10-K).
2017-10-19 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.